Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00366405
Other study ID # MRC-06-001
Secondary ID
Status Completed
Phase Phase 4
First received August 17, 2006
Last updated October 1, 2010
Start date February 2006
Est. completion date September 2007

Study information

Verified date October 2010
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the visual outcomes, amount of inflammation, endothelial cell loss, and the efficiency of a torsional handpiece compared to a conventional handpiece during surgery to remove your cataracts.


Description:

With the introduction of new phaco-emulsification systems, the cataract surgery has become a very safe procedure. The new machines combine fewer surges, lower amount of ultrasound and more controlled anterior chamber depth, as well as lower incidence of thermal burns of the incision site.1-4

Alcon's Infiniti Vision System phacoemulsification machine includes now a torsional handpiece (OZiLâ„¢). The goal of OZiLâ„¢ is to minimize the surgery impact by reducing temperature increase, turbulence and incision stress. This handpiece has a sideways movement that does not repel the cataract during its extraction making the removal more continuous, maintains occlusion which facilitates vacuum build-up and reduces flow through the anterior chamber decreasing turbulence, therefore reducing the likelihood of lens particles damaging the corneal endothelial cells.

The purpose of this study is to compare visual outcomes, induction of inflammation, endothelial cell loss and efficiency of the torsional handpiece vs. the conventional phacoemulsification handpiece when using the Alcon Infiniti Vision System.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Bilateral senile cataracts.

- Cataract density up to 3+.

- 50 years of age or older.

- Patient must desire cataract extraction.

- Expected maximum of 4 weeks and minimum of 1 week interval between first and second eye surgeries.

- Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

- Preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, macular edema, retinal detachment, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmus or macrophthalmus, optic nerve atrophy, macular degeneration with visual acuity of less than 20/40, glaucoma with the presence of visual field defects

- Corneal irregularities potentially affecting visual acuity: keratoconus, corneal dystrophy, corneal opacities.

- Low endothelial cell count (less than 1500 cells/mm2)

- Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in either eye.

- Any clinically significant, serious or severe medical or psychiatric condition.

- Participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial.

- Previous intraocular or corneal surgery.

- Other ocular surgery at the time of the cataract extraction.

Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Storm Eye Institute, Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT00924729 - Study of Ocular Penetration of Topically Administered Fluoroquinolones Phase 4
Completed NCT00524264 - A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery Phase 3
Completed NCT00565695 - Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction N/A
Completed NCT00521456 - A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery Phase 3
Completed NCT02973880 - Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction Phase 3
Completed NCT00721695 - Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification. Phase 1/Phase 2
Withdrawn NCT00466908 - Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery
Completed NCT00366665 - Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems N/A
Completed NCT05571683 - Cerebral Oxymeter and End Tidal Carbondioxide Values Under Surgical Drapes With and Without Past COVID-19 Infection
Not yet recruiting NCT04977115 - Clinical Evaluation of Intraocular Caliper-assisted Capsulotomy for Age-related Cataract N/A
Withdrawn NCT00366613 - Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation Phase 4
Completed NCT00366496 - Surgical Outcomes After Routine Cataract Extraction & Implantation of a Conventional or Spheric Intraocular Lens N/A
Not yet recruiting NCT03828500 - Preoperative Fasting for Ambulatory Cataract Surgery: The PRACTICE Study N/A
Completed NCT00840580 - Effect on Wound Healing of Vigamox Versus Cravit Phase 4
Completed NCT00842231 - Assessment of Visual Performance in Patients With Low Levels of Astigmatism N/A
Completed NCT00851760 - Epiretinal Macular Membrane and Cataract Extraction N/A
Recruiting NCT03944070 - Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery N/A
Completed NCT03364972 - A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00 N/A
Completed NCT00824070 - Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Phase 1
Completed NCT00366691 - Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Phase 4